Cargando…
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613116/ https://www.ncbi.nlm.nih.gov/pubmed/34694530 http://dx.doi.org/10.1007/s11523-021-00853-y |
| _version_ | 1784603570299994112 |
|---|---|
| author | Lamb, Yvette N. |
| author_facet | Lamb, Yvette N. |
| author_sort | Lamb, Yvette N. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8613116 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86131162021-12-10 Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC Lamb, Yvette N. Target Oncol Correction Springer International Publishing 2021-10-25 2021 /pmc/articles/PMC8613116/ /pubmed/34694530 http://dx.doi.org/10.1007/s11523-021-00853-y Text en © Springer Nature 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Lamb, Yvette N. Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC |
| title | Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC |
| title_full | Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC |
| title_fullStr | Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC |
| title_full_unstemmed | Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC |
| title_short | Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC |
| title_sort | correction to: osimertinib: a review in previously untreated, egfr mutation-positive, advanced nsclc |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613116/ https://www.ncbi.nlm.nih.gov/pubmed/34694530 http://dx.doi.org/10.1007/s11523-021-00853-y |
| work_keys_str_mv | AT lambyvetten correctiontoosimertinibareviewinpreviouslyuntreatedegfrmutationpositiveadvancednsclc |